July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
First-in-human laser-induced refractive index change (LIRIC) treatment of the cornea
Author Affiliations & Notes
  • Len Zheleznyak
    Clerio Vision, Inc., Rochester, New York, United States
  • Sam C Butler
    Clerio Vision, Inc., Rochester, New York, United States
  • Ian G Cox
    ICG Consulting, New York, United States
  • Krystel R Huxlin
    Flaum Eye Institute, University of Rochester, Rochester, New York, United States
  • Jonathan D Ellis
    College of Optical Sciences, University of Arizona, Arizona, United States
  • Wayne Knox
    Institute of Optics, University of Rochester, New York, United States
  • Kevin Waltz
    Ophthalmic Research Consultants, Indianapolis, Indiana, United States
  • John A. Vukich
    Davis Duehr Dean Center for Refractive Surgery, SSM Health Care, Madison, Wisconsin, United States
  • Gabriel Quesada
    Clinica Quesada, San Salvador, El Salvador
  • Rodrigo Quesada
    Clinica Quesada, San Salvador, El Salvador
  • Amarilis Melendez
    Clinica Quesada, San Salvador, El Salvador
  • Jeff J. Machat
    Crystal Clear Vision, Toronto, Ontario, Canada
  • Scott M. MacRae
    Flaum Eye Institute, University of Rochester, Rochester, New York, United States
  • Footnotes
    Commercial Relationships   Len Zheleznyak, Clerio Vision, Inc. (E), Clerio Vision, Inc. (I), Clerio Vision, Inc. (P); Sam Butler, Clerio Vision, Inc. (I), Clerio Vision, Inc. (E), Clerio Vision, Inc. (P); Ian Cox, Clerio Vision, Inc. (C); Krystel Huxlin, Clerio Vision, Inc. (F), Clerio Vision, Inc. (I), Clerio Vision, Inc. (P); Jonathan Ellis, Clerio Vision, Inc. (F), Clerio Vision, Inc. (C), Clerio Vision, Inc. (P), Clerio Vision, Inc. (R), Clerio Vision, Inc. (S); Wayne Knox, Clerio Vision, Inc. (F), Clerio Vision, Inc. (I), Clerio Vision, Inc. (C), Clerio Vision, Inc. (P), Clerio Vision, Inc. (R); Kevin Waltz, Clerio Vision, Inc. (F), Clerio Vision, Inc. (I), Clerio Vision, Inc. (R); John Vukich, Clerio Vision, Inc. (C); Gabriel Quesada, Clerio Vision, Inc. (C); Rodrigo Quesada, Clerio Vision, Inc. (C); Amarilis Melendez, Clerio Vision, Inc. (C); Jeff Machat, Allergan (C), ASICO (R), Avedro (C), Clerio Vision, Inc. (C), Clerio Vision, Inc. (R), Johnson & Johnson (C), Keeler (C), Schwind (C); Scott MacRae, Clerio Vision, Inc. (C)
  • Footnotes
    Support  NSF STTR Phase I: NSF/IIP 1549700; NSF STTR Phase II: NSF/IIP 1738506; CEIS: C090130; Research to Prevent Blindness
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5079. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Len Zheleznyak, Sam C Butler, Ian G Cox, Krystel R Huxlin, Jonathan D Ellis, Wayne Knox, Kevin Waltz, John A. Vukich, Gabriel Quesada, Rodrigo Quesada, Amarilis Melendez, Jeff J. Machat, Scott M. MacRae; First-in-human laser-induced refractive index change (LIRIC) treatment of the cornea. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5079.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Corneal laser induced refractive index change (LIRIC) has been previously demonstrated in cat and rabbit animal models and ex-vivo human cornea (previously known as IRIS). The present study is the first to assess the safety of performing LIRIC - a patterned, fs-laser induced refractive index modification of the cornea - in human patients.

Methods : Five partially-sighted pseudophakic eyes of 5 patients (3 female; age: 68±15yrs) were instilled with topical anesthetic (proparacaine, 0.5%), immobilized with a suction ring and flat applanated with a custom-built patient interface. All treated eyes had pre-existing low vision conditions such as macular holes. The LIRIC procedure did not require dopants, epithelial removal or flap cutting. Each eye was treated with an 82s duration exposure of a 405nm wavelength fs-laser focused in the central cornea (250µm depth). A custom-built system scanned the laser focal point across a 3mm diameter optical zone while simultaneously modulating laser power to impart a +2.5D diffractive bifocal wavefront. At the time of abstract submission, eye exams were performed pre-operatively, 1 day, and 1 week post-operatively, with remaining visits of 1, 3, 6 and 12 months to be conducted. To assess safety, eye exams included slit lamp imaging, anterior segment optical coherence tomography (OCT; Copernicus+, Optopol), pachymetry and topography (Galilei, Ziemer).

Results : All 5 patients were successfully treated with LIRIC. At all post-operative time points the cornea appeared clear under slit lamp examination. There was no evidence of corneal or conjunctival inflammation, scarring, or opacity. The LIRIC pattern was visible with slit lamp and OCT. Notably, there were no significant changes (paired Student’s t-test, p>0.60) in anterior corneal curvature (mean change: 0.08±0.38D), posterior corneal curvature (0.02±0.11D), or corneal central thickness (-3.8±15.9µm) between the pre-operative and 1 week post-operative time points.

Conclusions : The first-in-human study of LIRIC indicated a good, early safety profile with clear corneas, no evidence of inflammation, scarring, or opacity. Further studies are needed to assess visual efficacy and establish long-term stability. However, this study is an essential first step in establishing laser-induced refractive index change as a new, ablation-free, tissue-sparing method to correct ocular refractive errors without causing a change in corneal shape.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×